| 000 | 01592 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518030604.0 | ||
| 264 | 0 | _c20200803 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1873-3913 | ||
| 024 | 7 |
_a10.1016/j.cellsig.2019.03.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPandey, Vivek Kumar | |
| 245 | 0 | 0 |
_aActivation of PERK-eIF2α-ATF4 pathway contributes to diabetic hepatotoxicity: Attenuation of ER stress by Morin. _h[electronic resource] |
| 260 |
_bCellular signalling _c07 2019 |
||
| 300 |
_a41-52 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aActivating Transcription Factor 4 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntioxidants _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Experimental _xcomplications |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 | _aDown-Regulation |
| 650 | 0 | 4 |
_aEndoplasmic Reticulum Stress _xdrug effects |
| 650 | 0 | 4 |
_aFlavonoids _xpharmacology |
| 650 | 0 | 4 |
_aHyperglycemia _xcomplications |
| 650 | 0 | 4 |
_aLiver Diseases _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aStreptozocin |
| 650 | 0 | 4 |
_aeIF-2 Kinase _xantagonists & inhibitors |
| 700 | 1 | _aMathur, Alpana | |
| 700 | 1 | _aKhan, Mohammad Fareed | |
| 700 | 1 | _aKakkar, Poonam | |
| 773 | 0 |
_tCellular signalling _gvol. 59 _gp. 41-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cellsig.2019.03.008 _zAvailable from publisher's website |
| 999 |
_c29482941 _d29482941 |
||